Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.0%

4 terminated/withdrawn out of 25 trials

Success Rate

84.0%

-2.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

10%

2 of 21 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
22(88.0%)
Phase 2
3(12.0%)
25Total
Phase 1(22)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials
NCT00790049Phase 1Completed

A Safety Study of ARRY-371797 in Healthy Subjects

Role: lead

NCT00650767Phase 2Completed

A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

Role: lead

NCT02109653Phase 2Withdrawn

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Role: lead

NCT00278902Phase 1Completed

A Study of ARRY-334543 in Patients With Advanced Cancer

Role: lead

NCT00085787Phase 1Completed

A Study of ARRY-142886 in Patients With Advanced Cancer

Role: lead

NCT00637702Phase 1Completed

A Study of ARRY-334543 in Patients With Advanced Cancer

Role: lead

NCT00833326Phase 1Completed

A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer

Role: lead

NCT01556568Phase 2Withdrawn

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy

Role: lead

NCT00710736Phase 1Completed

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Role: lead

NCT00952198Phase 1Completed

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

Role: lead

NCT00828165Phase 1Completed

A Safety Study of ARRY-300 in Healthy Subjects

Role: lead

NCT01469130Phase 1Completed

A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors

Role: lead

NCT01363232Phase 1Completed

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Role: lead

NCT01349725Phase 1Completed

A Safety Study of ARRY-502 in Healthy Subjects

Role: lead

NCT01352273Phase 1Completed

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

Role: lead

NCT01248923Phase 1Completed

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT00462358Phase 1Completed

A Study of ARRY-520 in Patients With Advanced Cancer

Role: lead

NCT00729209Phase 1Completed

A Study of ARRY-371797 in Patients With Rheumatoid Arthritis

Role: lead

NCT01316822Phase 1Completed

A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Role: lead

NCT02050815Phase 1Terminated

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function

Role: lead